2-氨基-4,6-二甲基-3-吡啶甲酰胺 | 7144-20-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基-4,6-二甲基-3-吡啶甲酰胺
• 中文别名: 2-氨基-4,6-二甲基吡啶-3-甲酰胺
• 英文名称: 2-Amino-4,6-dimethylnicotinamide
• 英文别名: 2-Amino-4,6-dimethylpyridine-3-carboxamide
• CAS: 7144-20-9
• 化学式: C₈H₁₁N₃O
• mdl: MFCD00138572
• 分子量: 165.195
• InChiKey: UYDGECQHZQNTQS-UHFFFAOYSA-N

物化性质

• 熔点：
  172-174 °C
• 沸点：
  293.03°C (rough estimate)
• 密度：
  1.1669 (rough estimate)
• 稳定性/保质期：
  避免与不相容材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。

SDS

Name:	2-Amino-4 6-Dimethyl-3-Pyridinecarboxamide 93%(TLC) Material Safety Data Sheet
Synonym:	None known
CAS:	7144-20-9

Section 1 - Chemical Product MSDS Name:2-Amino-4 6-Dimethyl-3-Pyridinecarboxamide 93%(TLC) Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7144-20-9	2-Amino-4,6-Dimethyl-3-Pyridinecarboxa	93	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7144-20-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 154 - 157 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H11N3O
Molecular Weight: 165.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7144-20-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Amino-4,6-Dimethyl-3-Pyridinecarboxamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 7144-20-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7144-20-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7144-20-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用广泛，2-氨基-4,6-二甲基-3-吡啶甲酰胺可作为有机中间体和医药中间体，主要应用于实验室研发及化工生产过程。

反应信息

• 作为反应物：
  描述：

  2-氨基-4,6-二甲基-3-吡啶甲酰胺 在 碘苯二乙酸 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 以90%的产率得到5,7-二甲基-1H-咪唑并[4,5-B]吡啶-2(3H)-酮
  参考文献：
  名称：

  发现一系列在血管紧张素II 1型受体和过氧化物酶体增殖物激活的受体-γ上具有双重活性的咪唑并[4,5- b ]吡啶

  摘要：

  内部收集血管紧张素II 1型受体拮抗剂以鉴定对过氧化物酶体增殖物激活受体-γ（PPARγ）具有活性的化合物，发现了一系列新的咪唑并[4,5- b ]吡啶2在这些化合物上具有活性两个受体。与人PPARγ的配体结合域结合的前导化合物2a的晶体结构的早期可用性证实了该支架与核受体的相互作用方式，并有助于优化PPARγ活性。在新化合物中，（S）-3-（5-（2-（1 H-四唑-5-基）苯基）-2,3-二氢-1 H-茚满-1-基）-2-乙基- 5-异丁基-7-甲基-3 H-咪唑[4,5- b对吡啶（2l）被确定为有效的血管紧张素II型I受体阻滞剂（IC 50 = 1.6 nM），具有部分PPARγ激动作用（EC 50 = 212 nM，最大31％），并且在大鼠中具有口服生物利用度。在高血压（SHR）和胰岛素抵抗（ZDF大鼠）的动物模型中证实了2l的双重药理学。在SHR中，2l在降低血压方面非常有效，

  DOI：

  10.1021/jm200409s
• 作为产物：
  描述：

  乙酰丙酮 在 sodium hydroxide 、 乙醇 、 氢气 、 镍 作用下， 生成 2-氨基-4,6-二甲基-3-吡啶甲酰胺
  参考文献：
  名称：

  Synthesis of 2-Aminonicotinamides by Raney Nickel Cleavage of Pyrazolo[3,4-b]-pyridines¹

  摘要：

  DOI：

  10.1021/ja01519a043

文献信息

• [EN] NOVEL ANTI-INFLAMMATORY AGENTS<br/>[FR] NOUVEAUX AGENTS ANTI-INFLAMMATOIRES
  申请人：RESVERLOGIX CORP

  公开号：WO2010123975A1

  公开（公告）日：2010-10-28

  Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

  揭示了调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的方法，以及治疗和/或预防心血管和炎症性疾病及相关疾病状态的方法，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎症性肠病以及自身免疫疾病，通过给予天然存在或合成的喹唑啉衍生物。该发明提供了新颖的合成喹唑啉化合物，以及包含这些化合物的药物组合物。
• Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis
  作者：Wolfgang Miltz、Juraj Velcicky、Janet Dawson、Amanda Littlewood-Evans、Marie-Gabrielle Ludwig、Klaus Seuwen、Roland Feifel、Berndt Oberhauser、Arndt Meyer、Daniela Gabriel、Mark Nash、Pius Loetscher

  DOI：10.1016/j.bmc.2017.06.050

  日期：2017.8

  extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.

  GPR4是一种G蛋白偶联受体，起质子传感器的作用，可被细胞外酸性pH激活，并被认为在与多种炎性疾病相关的酸中毒中起着关键作用。从高通量筛选命中1开始，开发了一种口服活性GPR4拮抗剂39c。该化合物显示出有效的细胞活性，并且在血管生成，炎症和疼痛的动物模型中有效。
• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281398A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• [EN] BIARYLMETHYL HETEROCYCLES<br/>[FR] HÉTÉROCYCLES BIARYLMÉTHYLES
  申请人：UNIV MONTREAL

  公开号：WO2018005591A1

  公开（公告）日：2018-01-04

  The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

  本发明提供了式(I)的化合物：其中所有变量如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是肾素II受体的偏倚激动剂，或β-阻滞素激动剂，可用作药物。
• Synthesis of new 2-substituted pyrido[2,3-d]pyrimidin-4(1H)-ones and their antibacterial activity☆
  作者：B. Lakshmi Narayana、A. Raghu Ram Rao、P. Shanthan Rao

  DOI：10.1016/j.ejmech.2008.05.025

  日期：2009.3

  2-Substituted-5,7-dimethyl pyrido[2,3-d]pyrimidin-4(1H)-ones (8) were synthesized by oxidation of 2-substituted-5,7-dimethyl dihydropyrido[2,3-d]pyrimidin-4(1H)-ones (7) which were in turn prepared from 2-amino-4,6-dimethyl nicotinamide (5) and substituted aryl aldehydes (6). 2-Amino-4,6-dimethyl nicotinamide (5) was prepared from ethyl cyanoacetate (1) via malonamamidine hydrochloride (3). The compounds

  2-取代的-5,7-二甲基吡啶并[2,3- d ]嘧啶-4（1 ħ） -酮（8）通过2-取代-5,7-二甲基二氢吡啶氧化并[2,3-合成d ]嘧啶-4（1 H）-一（7），其依次由2-氨基-4,6-二甲基烟酰胺（5）和取代的芳基醛（6）制备。由氰基乙酸乙酯（1）通过丙二酸ama丙啶（3）制备2-氨基-4,6-二甲基烟酰胺（5）。通过IR，NMR，MS和元素分析对化合物进行表征。化合物7和8筛选针对革兰氏阳性和阴性细菌的抗菌活性。脱氢化合物（8）的抗菌活性低于化合物7。在所有筛选的具有抗菌活性的化合物中，7c（1.25μg/ ml）表现出更高的活性。当在200μg/ ml的浓度下筛选抗真菌活性时，发现所有合成的化合物均无活性。